BioSpace News Archive

CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.

PTC Therapeutics, Inc. announced the appointment of Pierre Gravier to the role of Chief Financial Officer.

Endo International plc and Premier, Inc. announced that Endo’s Par Sterile Products business will supply Pitocin® vials through Premier’s ProvideGx® and PremierProRx® programs.

Acumen Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.

The National Evaluation System for health Technology Coordinating Center announced it released a Request for Proposal as part of an ongoing collaboration between the FDA’s Center for Devices and Radiological Health that focuses on the Central Data Operations Hub as part of its Active Surveillance Program for medical devices.

SK Biopharmaceuticals announced that it has unveiled its new strategy that will enable the company take a leap toward becoming a global “big biotech.”

Camurus announced topline, interim data from an open-label, long-term safety and extension trial, ACROINNOVA 2, assessing CAM2029, octreotide subcutaneous depot, in 135 adult patients with acromegaly.

GeneQuantum and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, signed a collaboration agreement.

Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, announced that it will report financial results and provide a corporate update for the second quarter ended June 30, 2023.

Clearside Biomedical, Inc. announced today that the enrollment and dosing of participants is underway in ODYSSEY, its randomized, Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD).